Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Prostatic Neoplasms 6 Neoplasms by Histologic Type 2 Neoplasms 2 Lymphoproliferative Disorders 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Lymphatic Diseases 2 Immune System Diseases 2 Gastro-enteropancreatic neuroendocrine tumor 2 AIDS-Related Complex 2 Urogenital Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Recurrence 1 Prostatic Diseases 1 Prostate Cancer Metastatic 1 Pheochromocytoma 1 Paraganglioma 1 Neuroendocrine Tumors 1 Metastatic Neuroendocrine Prostate Cancer 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Metastatic Castration-Resistant Prostate Cancer 1 Metastatic Castration Resistant Prostate Cancer (mCRPC) 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lung Neoplasms 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Immunoproliferative Disorders 1

Interventions

lutetium Lu 177 dotatate 34 Everolimus 33 lanreotide 13 gallium Ga 68 dotatate 13 Temozolomide 13 Magnetic Resonance Spectroscopy 13 Nivolumab 12 pembrolizumab 11 Octreotide 11 Capecitabine 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 10 cabozantinib 9 Positron Emission Tomography Computed Tomography 9 3-Iodobenzylguanidine 9 surufatinib 8 Sunitinib 8 Specimen Handling 7 Carboplatin 7 pasireotide 6 amino-acid, glucose, and electrolyte solution 6 90Y-octreotide, DOTA-Tyr(3)- 6 lenvatinib 5 Lutetium-177 5 Ipilimumab 5 Fluorodeoxyglucose F18 5 Etoposide 5 Cisplatin 5 Bevacizumab 5 telotristat ethyl 4 olaparib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neuroendocrine Tumors × Lutetium × Clear all

NCT06878664 2025-09-02

RIALTO

Grupo Espanol de Tumores Neuroendocrinos

Phase 3 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡